PharmaEssentia Corporation (6446.TW) Stock
PharmaEssentia Corporation

Company profile
PharmaEssentia reported revenue of 9.73 billion TWD for fiscal year 2024. In Q2 2025 (the quarter ended June 30, 2025) revenue was 3.60 billion TWD. America was its largest region in fiscal year 2025, with 77% of revenue. In Q2 2025 it reported net income of 832.25 million TWD, against net income of 679.82 million TWD a year earlier. Our analysis of its filings shows revenue growing from 2.88 billion TWD in fiscal year 2022 to 9.73 billion TWD in fiscal year 2024, 83.8% a year on average.
What stands out
- Revenue rose 90.7% in fiscal year 2024, from 5.11 billion TWD in fiscal year 2023, after a rise of 77.2% the year before.
- It returned to a profit in fiscal year 2024, 2.97 billion TWD, after 4 years of net losses (623.84 million TWD in fiscal year 2023).
- Revenue growth slowed in Q2 2025: up 56.2% from a year before.
- It spent 2.59 billion TWD on research and development in fiscal year 2024, 26.6% of its revenue.
Figures from company filings; latest fiscal year ended December 31, 2024.
About PharmaEssentia Corporation
PharmaEssentia Corporation, a biopharmaceutical company engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug patterns developments in the Americas, Europe, Asia, and Taiwan. Its products include BESREMi, an interferon therapy indicated for polycythemia vera, essential thrombocythemia, PMF, and adult T-cell leukemias. The company also develops Ropeg + anti PD-1; PEG-IL-2 (P11838); PEG-Cytokines; PD-1-IL-2v; ADC; ADCS; NY-ESO-1 TCR-T; and Novel TCR-T for the treatment of solid tumor and immunology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.
Largest shareholders
- National Development Fund of The Executive Yuan6.27%
- Eon Capital Group Ltd.1.67%
- Kuo Chung Lin1.345 %1.34%
- Ching-Leou Teng1.042 %1.04%
- Cheng Ku Huang0.6157 %0.62%
Share of the company, as of September 25, 2026
Leadership
- Ko-Chung Lin Ph.D. — Founder, CEO, Chief Strategy Officer & Director
- Chan-Kou Hwang Ph.D. — President, GM & Director
- Ching-Leou Teng Ph.D. — Chairman & Chief Pharmaceutical Officer
- Lih-Ling Lin Ph.D. — Chief Scientific Officer
- Albert Qin M.D., Ph.D. — Chief Medical Officer
In the news
How much revenue does PharmaEssentia make?
PharmaEssentia reported 9.73 billion TWD in revenue for fiscal year 2024, up 90.7% from 5.11 billion TWD in fiscal year 2023. In Q2 2025 revenue was 3.60 billion TWD.
Where does PharmaEssentia make most of its revenue?
America: 77% of revenue by region in fiscal year 2025, followed by Europe (12%).
What companies are similar to PharmaEssentia?
Listed companies of a similar size in the same industry (blood disorder treatment drugs) include Tanvex BioPharma, Inc. (6541.TW).
How has PharmaEssentia's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2020, 557.26 million TWD; FY2021, 656.51 million TWD; FY2022, 2.88 billion TWD; FY2023, 5.11 billion TWD; FY2024, 9.73 billion TWD.
Has PharmaEssentia made a profit in recent years?
Net income by fiscal year: FY2020, a loss of 1.95 billion TWD; FY2021, a loss of 2.81 billion TWD; FY2022, a loss of 1.37 billion TWD; FY2023, a loss of 623.84 million TWD; FY2024, 2.97 billion TWD. It reported a net loss in 4 of these 5 years.
Company Information
Data as of .
How to cite: DataPorium, “PharmaEssentia Corporation (6446.TW)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/6446.TW